Bladder malignancy in a patient receiving low dose cyclophosphamide for treatment of rheumatoid arthritis

Ansher, Alan F.; Melton, John W.; Sliwinski, Anthony J.

doi:10.1002/art.1780260618

Cited by 15 publications

(4 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Immunosuppression medication has been implicated in malignant development. Several case reports have identified cyclophosphamide as a possible cause of TCC in renal transplant patients [42–44]. It is possible that urinary metabolites of cyclophosphamide have a carcinogenic effect on the urothelium.…”

Section: Discussionmentioning

confidence: 99%

The management of transitional cell carcinoma (TCC) in a European regional renal transplant population

Rogers¹,

Glendinning

et al. 2012

BJU International

View full text Add to dashboard Cite

Study Type – Therapy (prospective cohort) Level of Evidence 2a What's known on the subject? and What does the study add? In the West, transitional cell carcinoma (TCC) in renal transplant patients is uncommon, but aggressive. Conversely, it appears to be frequent in the Far East, necessitating aggressive surgical approaches such as prophylactic nephroureterectomy. There are few European case series to date. TCC in the present population was predominantly low‐grade and superficial, with no progression in patients with those tumours. Endoscopic management was sufficient for most patients. The behaviour of TCC in the present population was much less aggressive than that described in the Far East. Altering immunosuppression regimes may have a role to play in managing bladder cancer in renal transplant patients. OBJECTIVE To examine the clinical characteristics, management and long‐term outcomes of patients with transitional cell carcinoma (TCC) who also have had renal transplantation. PATIENTS AND METHODS A retrospective case note review was performed for the 15‐year period 1995–2009. Searches from three different urological centres in the UK, using multiple sources, yielded 1647 patients with renal transplants, 12 of whom had TCC. Eight cases were identified who developed de novo TCC after transplantation (0.48%). Four patients had pre‐existing TCC who then had renal transplantation. The current literature was reviewed. RESULTS In the eight de novo TCC cases, the bladder was the site in all with no upper tract TCC; seven were superficial (pTa/T1) and five were low grade (G1/2). The mean time to development of TCC after transplant was 5 years, with a mean follow‐up of 11 years. There was no progression in low‐grade superficial disease that was managed endoscopically. The 5‐ and 10‐year overall survival was 83% and 72%, respectively. In patients with pre‐existing TCC prophylactic bilateral nephroureterectomy before transplantation was performed once. There was progression of superficial disease whilst on immunosuppression in one patient. Sirolimus was used in patients with TCC and reports suggest this may have a role to play in modifying malignancy in this setting. The number of patients involved in studies particularly focusing on TCC in renal transplantation is small (136 patients), with 60% from China/Taiwan where there is a high incidence of upper tract TCC and high‐grade muscle‐invasive disease. CONCLUSIONS Although this is one of the largest European case series of renal transplant patients with TCC, the numbers are small making clear conclusions difficult. The frequency of TCC in our renal transplant population is low, consistent with previous studies. However, contrary to prior studies, TCC after renal transplantation in this European population was predominantly superficial, low‐grade, non‐progressive and confined to the bladder. Altering immunosuppression regimes in patients with TCC may have a role to play, although further work is required to clarify and substantiate this.

show abstract

Section: Discussionmentioning

confidence: 99%

The management of transitional cell carcinoma (TCC) in a European regional renal transplant population

Rogers¹,

Glendinning

et al. 2012

BJU International

View full text Add to dashboard Cite

show abstract

“…Previously, an increased risk of urinary bladder cancer has been suggested among patients with rheumatoid arthritis treated with cyclophosphamide (32,33). Kinlen (34) reported no patient with urinary bladder cancer versus 0.68 expected among rheumatoid arthritis patients treated with the immunosuppressive drug azathloprine.…”

Section: Discussionmentioning

confidence: 99%

Acetaminophen, Some other Drugs, Some Diseases and the Risk of Transitional Cell Carcinoma: A population-based case-control study

Steineck

1995

Acta Oncologica

View full text Add to dashboard Cite

“…1 2 Likewise, reports on other rheumatological conditions are limited to a handful of observed cases of bladder cancer. [6][7][8] Because cyclophosphamide has markedly improved survival in Wegener's granulomatosis, and remains the mainstay induction treatment, not only for generalised Wegener's granulomatosis but also for a series of manifestations of more common rheumatological diseases, the prevalence of subjects with a history of cyclophosphamide exposure is likely to increase substantially. It has therefore become increasingly important to assess accurately, and to attribute, the risks associated with cyclophosphamide use.…”

mentioning

confidence: 99%

Urinary bladder cancer in Wegener's granulomatosis: risks and relation to cyclophosphamide

Knight

Askling

Granath

et al. 2004

Annals of the Rheumatic Diseases

181

112

View full text Add to dashboard Cite

Bladder malignancy in a patient receiving low dose cyclophosphamide for treatment of rheumatoid arthritis

Cited by 15 publications

References 11 publications

The management of transitional cell carcinoma (TCC) in a European regional renal transplant population

The management of transitional cell carcinoma (TCC) in a European regional renal transplant population

Acetaminophen, Some other Drugs, Some Diseases and the Risk of Transitional Cell Carcinoma: A population-based case-control study

Urinary bladder cancer in Wegener's granulomatosis: risks and relation to cyclophosphamide

Contact Info

Product

Resources

About